Next week we will annotate regulatory interactions in prostate cancer. Prostate cancer (PCa) is considered the most prevalent malignancy and the second major cause of cancer-related death in males from Western countries. Androgen deprivation therapy (ADT) is the primary treatment option for male patients with advanced symptomatic PCa. Castration-resistant prostate cancer (CRPC) refers to the continuous progression of PCa following ADT. We will focus on the role of non-coding RNAs and transcription factors in prostate cancer development and progression.